This study is looking at ways to help men with prostate cancer complete recommended germline genetic testing. Germline genetic testing checks for inherited gene changes that can affect your cancer treatment and help identify family members who might also be at risk. The study will develop and test a decision support tool, which is a resource designed to educate you and help you decide about genetic testing. Researchers want to understand what helps or hinders patients from getting tested and how well this new tool works to improve testing rates. The study involves men with prostate cancer receiving care at Lyndon B. Johnson (LBJ) Hospital who have been recommended for genetic testing by their doctor. The main goal is to see how safe the study procedures are over about one year.

Study design

This study plans to enroll 108 men and is an interventional study, meaning participants will receive a specific intervention. It is structured into three groups, with two observational and one pilot intervention group.

What's involved

You might participate in interviews, view a draft or final decision support tool, and provide a blood sample. You will also meet with a genetic counselor and undergo standard genetic testing.

Compensation

Not stated in the trial record.

Follow-up

Your safety and any side effects will be monitored through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.